Improving CAR T-Cell Therapy Referral and Care Coordination in the Mountain West-CAR T Collaborative Care Webinar

Video Transcription

Video Summary

The webinar, <em>Strengthening Collaborative Care Pathways for CAR T Cell Therapy in the Mountain West</em>, focused on improving referral, treatment, and follow-up for CAR T patients across rural and community settings. Speakers from academic and community centers described the growing impact of CAR T therapy in lymphoma and myeloma, noting major survival gains compared with pre-CAR T treatment.

A key theme was the importance of early referral and timely coordination, since outcomes worsen when there is too much delay between relapse and infusion. Presenters outlined the CAR T care continuum: referral, evaluation, apheresis, manufacturing, bridging therapy, infusion, and close monitoring.

Community clinicians emphasized the logistical barriers in the Mountain West, including travel distance, caregiver burden, poverty, and limited local resources. They discussed creative solutions such as telehealth, local labs and imaging, nonprofit support, and stronger relationships with tertiary centers.

The panel also reviewed recent FDA REMS changes, which reduced required proximity and driving restrictions after infusion. While these changes may allow patients to return home sooner, speakers stressed that not all patients are ready at 14 days. Safe transitions depend on clear discharge summaries, warm handoffs, shared responsibility, and close communication about infections, cytopenias, neurotoxicity, IVIG, and other delayed complications.

Meta Tag

CAR T 1

CAR T-cell therapy 1

Keywords

CAR T cell therapy

collaborative care pathways

early referral

rural oncology

Mountain West

telehealth

FDA REMS changes

post-infusion monitoring

1